Sign Up to like & get recommendations! 0
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz239.062
Abstract: Abstract Background Inflammation has a significant impact on cervical cancer (CC) development and therapy response. We sought to determine if splenic metabolic activity reflects host immune status and could improve prognostic and predictive categorization of… read more here.
Sign Up to like & get recommendations! 1
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz244.016
Abstract: Abstract Background ErbB3, a heterodimeric partner of EGFR or ErbB2, is activated by heregulin binding in various cancers. ISU104, blocking ErbB3 activation and dimerization, showed anti-tumor effects in various preclinical models as mono- or combination-therapy.… read more here.
Sign Up to like & get recommendations! 1
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz246.062
Abstract: Abstract Background Biomarkers associated to antiangiogiogenic agents in metastatic colorectal cancer (mCRC) have not yet been validated Here we present the efficacy and safety results of FOLFIRI and aflibercept in second line therapy for mCRC… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz250.038
Abstract: Abstract Background Retreatment with PLD in ROC has raised potential concerns of increased toxicity and diminished response rates. This subgroup analysis examined the safety and efficacy of platinum-sensitive patients (pts) with prior PLD therapy who… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz265.003
Abstract: Abstract Background The adverse events generated by immunotherapies are characterized by their wide diversity, unpredictability and reversibility by steroid used, and requires a delicate management. A collaborative organization of immunological toxicology management called ImmunoTOX (iTox)… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz266.014
Abstract: Abstract Background Thymic Epithelial Tumors (TETs) are rare entities, which can be diagnostic challenges for Pathologists. It has been proven that patients’ referral to a Center with an expert Pathologist is a key factor in… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz276.004
Abstract: Abstract Background PD(L)1-inhibitors can cause immune-related adverse events (irAEs.). IrAEs may be under-recognized and their influence on health-related quality of life (HRQL) underestimated. At this point, insight into patient-reported symptom prevalence and intensity is limited.… read more here.
Sign Up to like & get recommendations! 1
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz434.030
Abstract: Abstract Background Patients with malignant tumours may suffer from nausea as a side-effect of chemo-/radiotherapy. Antiemetic drugs can cause dizziness, which may lead to falls and decrease quality of life. Complementing research on painkiller-associated dizziness… read more here.